Clinical Data Signs Collaboration, Licensing Agreement With CombinatoRx

Clinical Data has entered into a collaboration and licensing agreement with CombinatoRx to develop an adenosine A2A agonist compound in a combination therapy. It is intended for the treatment of multiple myeloma and other B-cell cancers.

Under the agreement, Clinical Data licensed its adenosine A2A agonist – ATL313 to CombinatoRx, in exchange for the potential to receive up to $252m in clinical, regulatory and commercial milestones, as well as royalties on product sales.

Reportedly, Clinical Data also retains a co-development option, which is exercisable after review of any phase IIa study results. As part of the agreement, Clinical Data will contribute ATL313, a late-stage, preclinical compound.

Under the collaboration, CombinatoRx will be responsible for the preclinical and clinical development of ATL313, to potentially treat B-cell malignancies.

Research has shown that a combination drug approach utilizing adenosine A2A agonists as a component of a combination therapy, could be beneficial in the treatment of multiple myeloma.

Drew Fromkin, president and CEO of Clinical Data, said: Adenosine A2A agonists have shown tremendous promise in the development of therapeutics to treat a variety of diseases including cancer, inflammation, and pain disorders. We are pleased to continue to leverage the value of our highly selective adenosine pipeline by working with CombinatoRx to develop new therapies for multiple myeloma and other B-cell malignancies.”